Literature DB >> 14662322

SHIP, SHIP2, and PTEN activities are regulated in vivo by modulation of their protein levels: SHIP is up-regulated in macrophages and mast cells by lipopolysaccharide.

Laura M Sly1, Michael J Rauh, Janet Kalesnikoff, Tom Büchse, Gerald Krystal.   

Abstract

The phosphatidylinositol-3 kinase (PI3K) pathway plays a central role in regulating numerous biologic processes, including survival, adhesion, migration, metabolic activity, proliferation, differentiation, and end cell activation through the generation of the potent second messenger PI-3,4,5-trisphosphate (PI-3,4,5-P(3)). To ensure that activation of this pathway is appropriately suppressed/terminated, the ubiquitously expressed 54-kDa tumor suppressor PTEN hydrolyzes PI-3,4,5-P(3) to PI-4,5-P(2), whereas the 145-kDa hematopoietic-restricted SH2-containing inositol 5'-phosphatase SHIP (also known as SHIP1), the 104-kDa stem cell-restricted SHIP sSHIP, and the more widely expressed 150-kDa SHIP2 break it down to PI-3,4-P(2). In this review, we focus on the properties of these phospholipid phosphatases and summarize recent data showing that the activities of these negative regulators often are modulated by simply altering their protein levels. We also highlight the critical role that SHIP plays in lipopolysaccharide-induced macrophage activation and in endotoxin tolerance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14662322     DOI: 10.1016/j.exphem.2003.09.011

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  26 in total

Review 1.  Molecular underpinning of B-cell anergy.

Authors:  Yuval Yarkoni; Andrew Getahun; John C Cambier
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

Review 2.  Macrophage polarization: the link between inflammation and related diseases.

Authors:  Samina Bashir; Yadhu Sharma; Asif Elahi; Farah Khan
Journal:  Inflamm Res       Date:  2016-01       Impact factor: 4.575

Review 3.  MicroRNAs: the fine-tuners of Toll-like receptor signalling.

Authors:  Luke A O'Neill; Frederick J Sheedy; Claire E McCoy
Journal:  Nat Rev Immunol       Date:  2011-02-18       Impact factor: 53.106

Review 4.  IgE-dependent signaling as a therapeutic target for allergies.

Authors:  Donald W MacGlashan
Journal:  Trends Pharmacol Sci       Date:  2012-06-30       Impact factor: 14.819

5.  A key role for the phosphorylation of Ser440 by the cyclic AMP-dependent protein kinase in regulating the activity of the Src homology 2 domain-containing Inositol 5'-phosphatase (SHIP1).

Authors:  Jun Zhang; Kodi S Ravichandran; James C Garrison
Journal:  J Biol Chem       Date:  2010-09-01       Impact factor: 5.157

6.  Upregulation of immunoregulatory Src homology 2 molecule containing inositol phosphatase and mononuclear cell hyporesponsiveness in oral mucosa during chronic periodontitis.

Authors:  Manoj Muthukuru; Christopher W Cutler
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

7.  Inositol phosphatase SHIP1 is a primary target of miR-155.

Authors:  Ryan M O'Connell; Aadel A Chaudhuri; Dinesh S Rao; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

8.  Regulation of the Src homology 2 domain-containing inositol 5'-phosphatase (SHIP1) by the cyclic AMP-dependent protein kinase.

Authors:  Jun Zhang; Scott F Walk; Kodi S Ravichandran; James C Garrison
Journal:  J Biol Chem       Date:  2009-06-03       Impact factor: 5.157

9.  Mal connects TLR2 to PI3Kinase activation and phagocyte polarization.

Authors:  Sandra Santos-Sierra; Sachin D Deshmukh; Julia Kalnitski; Peter Küenzi; Matthias P Wymann; Douglas T Golenbock; Philipp Henneke
Journal:  EMBO J       Date:  2009-07-02       Impact factor: 11.598

10.  Cultured peripheral blood mast cells from chronic idiopathic urticaria patients spontaneously degranulate upon IgE sensitization: Relationship to expression of Syk and SHIP-2.

Authors:  Sarbjit S Saini; Miya Paterniti; Kavitha Vasagar; Scott P Gibbons; Patricia M Sterba; Becky M Vonakis
Journal:  Clin Immunol       Date:  2009-05-27       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.